Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | GAPDH | P04406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261313 | 0.77 | HIF1A (0.57) | HIF1AGAPDH | |
| SCHEMBL18009714 | 0.74 | PI4KA (0.49) | HIF1AGAPDH | |
| SCHEMBL13260665 | 0.72 | PDE2A (0.41) | — | |
| SCHEMBL12261152 | 0.69 | ADORA2A (0.47) | HIF1AGAPDH | |
| SCHEMBL12261248 | 0.68 | ADORA2A (0.40) | HIF1AGAPDH | |
| SCHEMBL12310541 | 0.66 | DNPH1 (0.38) | — | |
| SCHEMBL12261214 | 0.66 | PI4KA (0.37) | HIF1A | |
| SCHEMBL15899073 | 0.65 | SMN1; SMN2 (0.39) | HIF1AGAPDH | |
| SCHEMBL15898780 | 0.65 | SMN1; SMN2 (0.39) | HIF1AGAPDH | |
| SCHEMBL12261243 | 0.64 | PDE2A (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140170148-A1 | BISPECIFIC ANTIBODIES AGAINST HER2 | GENMAB A/S (DK) | 2014-06-19 | — | — | US | disclosed |
| WO-2010093608-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140170148-A1 | BISPECIFIC ANTIBODIES AGAINST HER2 | ERBB2, EGFR, ERBB3 | HIF1A 806/4885GAPDH 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.